ACM
HAE icon

ADI Capital Management’s Haemonetics HAE Stock Holding History

ADI Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-73,366
Closed -$3.29M – 16
2017
Q3 		$3.29M Buy
73,366
+2,400
+3% +$99.7K 1.63% 18
2017
Q2 		$2.8M Hold
70,966
– – 1.6% 17
2017
Q1 		$2.88M Buy
+70,966
New +$2.77M 1.67% 19

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADI Capital Management's HAE Position: Q4 2017 in Review

ADI Capital Management sold out of Haemonetics (HAE) in Q4 2017, closing a stake of 73,366 shares — an estimated $3.29M sold.

ADI Capital Management first reported a position in HAE in Q1 2017 and held it in 3 quarters. The position peaked at $3.29M in Q3 2017. 246 funds tracked by Wall St. Rank hold HAE as of Q4 2017.

  • ADI Capital Management reported no remaining Haemonetics position as of Q4 2017 after selling out during the quarter.
  • ADI Capital Management sold 73,366 Haemonetics shares in Q4 2017, an estimated $3.29M.
  • ADI Capital Management first reported a position in Haemonetics in Q1 2017 and held it in 3 quarters.
  • ADI Capital Management's Haemonetics position peaked at $3.29M in Q3 2017.
  • 246 funds tracked by Wall St. Rank held Haemonetics as of Q4 2017.

Based on ADI Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.